Alicia Beth Lichvar

Alicia Beth Lichvar

Auto-generated profile, based on publicly available information

Alicia Beth Lichvar

Center for Transplantation University of California San Diego Health La Jolla California USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in American Journal of Pharmaceutical Education
Verified
Journal Article
Open access
PDF file
ALAlicia Beth Lichvar
Alicia Beth Lichvar
AHAshley Hedges
Ashley Hedges
NBNeal J. Benedict
Neal J. Benedict
ADAmy C. Donihi
Amy C. Donihi
Objective. To design and evaluate the integration of a virtual patient activity in a required therapeutics course already using a flipped-classroom teaching format. Design. A narrative-branched, dynamic virtual-patient case was designed to replace the static written cases that students worked through during the class, which was dedicated to teaching the complications of liver disease. Students completed pre- and posttests before and after completing the virtual patient case. Examination scores were compared to those in the previous year. Assessment. Students’ posttest scores were higher compared to pretest scores (33% vs 50%). Overall median examination scores were higher compared to the historical control group (70% vs 80%), as well as scores on questions assessing higher-level learning (67% vs 83%). A majority of students (68%) felt the virtual patient helped them apply knowledge gained in the pre-class video lecture. Students preferred this strategy to usual in-class activities (33%) or indicated it was of equal value (37%). Conclusion. The combination of a pre-class video lecture with an in-class virtual patient case is an effective active-learning strategy.

22 February 2017 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
CEChristopher R. Ensor
Christopher R. Ensor
LRLindsey C. Rihtarchik
Lindsey C. Rihtarchik
MMMatthew R. Morrell
Matthew R. Morrell
JHJ. W. Awori Hayanga
J. W. Awori Hayanga
ALAlicia B. Lichvar
Alicia B. Lichvar
JMJohn F. McDyer
John F. McDyer

5 September 2016 in Progress in Transplantation
Verified
Journal Article
Closed access
ALAlicia B. Lichvar
Alicia B. Lichvar
CMCody A. Moore
Cody A. Moore
CEChristopher R. Ensor
Christopher R. Ensor
JMJohn F. McDyer
John F. McDyer
JTJeffrey J. Teuteberg
Jeffrey J. Teuteberg
MSMichael A. Shullo
Michael A. Shullo
Anticoagulation therapy is common in thoracic transplant recipients. Direct oral anticoagulants (DOACs) are alternatives to warfarin therapy, but characterization of their use in solid organ transplant is absent. The primary objective of this study was to describe a thoracic transplant patient population initiated on DOAC therapy. Secondary objectives were to assess adverse reactions, venous thromboembolism (VTE) recurrence, and drug–drug interactions during DOAC therapy. Single-center retrospective cohort study. A tertiary care medical center including inpatient hospitalization and outpatient transplant clinic visits. Thoracic transplant recipients who were initiated on DOACs between May 1, 2011, and March 1, 2015, at the University of Pittsburgh Medical Center were included. A total of 37 patients were included in the analysis. A majority of the patients were lung transplant recipients (86.4%) with a median age of 60.7 years. Twenty-eight patients had a history of VTE. The primary indication for DOAC initiation was VTE (86.5%). Rivaroxaban (78.4%) was the most commonly utilized agent. Dose reductions for major drug interactions (37.8%), renal insufficiency (10.8%), or both (8.1%) occurred within the study. Two patients had breakthrough VTE during DOAC therapy. Eight bleeding events were reported in the cohort, one of which was considered a major bleed. There was no difference in the incidence of bleeding in patients with drug–drug interactions and without drug–drug interactions during DOAC therapy (26.0% vs 7.1%, P = .154). Direct oral anticoagulant therapy was well tolerated by thoracic transplant recipients. Drug interactions and renal dose adjustments were common.

2 May 2017 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
TDTayyab S. Diwan
Tayyab S. Diwan
ALAlicia B. Lichvar
Alicia B. Lichvar
ALAbbie D. Leino
Abbie D. Leino
AVAlexander A. Vinks
Alexander A. Vinks
UCUwe Christians
Uwe Christians
RARita R. Alloway
Rita R. Alloway

12 March 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ALAlicia B. Lichvar
Alicia B. Lichvar
DPDana R. Pierce
Dana R. Pierce
DSDavid Salerno
David Salerno
PKPatrick Klem
Patrick Klem
GWGeorgina Waldman
Georgina Waldman
JPJeong M. Park
Jeong M. Park

6 November 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
ABAlexandra L. Bixby
Alexandra L. Bixby
ALAlicia B. Lichvar
Alicia B. Lichvar
DSDavid Salerno
David Salerno
JPJeong M. Park
Jeong M. Park